---
title: "JIAODA ONLLY: The company's current production and business activities are operating normally"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/243857083.md"
description: "JIAODA ONLLY issued a notice of unusual movement. After the company's self-examination, all production and operational activities are currently normal, with no significant adjustments in the market environment or industry policies, and no substantial fluctuations in production costs and sales. The internal production and operational order is normal. As of the date of this announcement, there are no significant matters affecting the abnormal fluctuations in the company's stock trading price; there is no other significant information related to the company that should be disclosed but has not been disclosed"
datetime: "2025-06-10T09:35:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/243857083.md)
  - [en](https://longbridge.com/en/news/243857083.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/243857083.md)
---

# JIAODA ONLLY: The company's current production and business activities are operating normally

JIAODA ONLLY issued a notice of unusual movements. After the company's self-examination, all production and operational activities are currently normal, with no significant adjustments in the market environment or industry policies, and no substantial fluctuations in production costs and sales. The internal production and operational order is normal. As of the date of this announcement, there are no significant matters affecting the abnormal fluctuations in the company's stock trading price; there is no other significant information related to the company that should be disclosed but has not been disclosed

### Related Stocks

- [600530.CN](https://longbridge.com/en/quote/600530.CN.md)

## Related News & Research

- [Shanghai Henlius says China regulator clears HLX48 Phase 1 trial IND for solid tumors](https://longbridge.com/en/news/287189347.md)
- [Orion Pharma to reveal initial results from Phase 1/2 TEADES study of ODM-212 at 2026 ASCO® Meeting.](https://longbridge.com/en/news/287177935.md)
- [Sparebanken Øst Boosts Employee Savings Scheme With Equity Certificate Buyback](https://longbridge.com/en/news/287108450.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [METALS-London copper extends losses on weak Chinese data](https://longbridge.com/en/news/286848628.md)